Mechanisms Behind IllnessInduced Anorexia

Loss of appetite, medically termed anorexia, commonly accompanies acute and chronic illnesses. While the word anorexia today often evokes an eatingdisorder, in clinical medicine it describes any reduction in food intake caused by disease processes. The mechanisms are multifactorial, intertwining peripheral signals from the sick organ with central pathways that regulate hunger, satiety, and motivation.

1. Peripheral Signals that Suppress Appetite

1.1 Cytokines and Inflammatory Mediators

Infection, autoimmune disease, and cancer trigger the release of proinflammatory cytokines such as interleukin1 (IL1), tumor necrosis factor (TNF), and interleukin6 (IL6). These molecules act on the hypothalamus and brainstem to decrease neuropeptide Y (NPY) and agoutirelated peptide (AgRP) two potent orexigenic (appetitestimulating) neuropeptides while increasing anorexigenic signals like proopiomelanocortin (POMC) and cocaine and amphetamineregulated transcript (CART).

1.2 Hormones of the Stress Axis

Illness activates the hypothalamicpituitaryadrenal (HPA) axis, raising cortisol and catecholamine levels. Elevated cortisol can blunt ghrelin (the hunger hormone) signaling, whereas norepinephrine directly suppresses feeding circuits in the nucleus of the solitary tract (NTS).

1.3 Gastrointestinal Factors

• Motilin & Peptide YY (PYY): Inflammation or obstruction slows gastric emptying, leading to early satiety and increased PYY release, a peptide that signals fullness.
• Enteric Hormones: Conditions such as gastroparesis or viral gastroenteritis raise levels of glucagonlike peptide1 (GLP1), which reduces appetite via vagal afferents.

1.4 Metabolic Byproducts

Accumulation of lactate, uremic toxins, or bilirubin in severe systemic disease can directly affect the chemosensory pathways of the NTS, making food less appealing.

2. Central Neural Pathways

2.1 Hypothalamic Integration

The arcuate nucleus (ARC) contains two opposing neuronal populations: NPY/AgRP (stimulate intake) and POMC/CART (inhibit intake). Peripheral signals shift the balance toward POMC activation during illness, lowering hunger.

2.2 Brainstem Satiety Centers

The dorsal vagal complex, especially the NTS, receives visceral afferents via the vagus nerve. Inflammation enhances glutamatergic transmission here, reinforcing signals of fullness.

2.3 Reward System Disruption

Dopaminergic pathways in the ventral tegmental area (VTA) and nucleus accumbens normally assign pleasure to eating. Cytokines reduce dopamine synthesis and release, making food less rewarding.

2.4 Taste and Smell Alterations

Illness often blunts taste (dysgeusia) and smell (anosmia) through cytokinemediated changes in olfactory epithelium and gustatory receptors, decreasing the hedonic value of food.

3. DiseaseSpecific Mechanisms

3.1 Infections

Acute bacterial or viral infections raise IL1 and TNF. Fever further reduces appetite by increasing metabolic demand while simultaneously signaling the brain that food intake is nonessential.

3.2 Cancer Cachexia

Beyond cytokines, tumors secrete proteolysisinducing factor (PIF) and lipidmobilizing factor (LMF). These act centrally to increase melanocortin signaling and peripherally cause muscle wasting, creating a vicious cycle of reduced intake and weight loss.

3.3 Chronic Heart Failure

Reduced perfusion of the gastrointestinal tract leads to edema and early satiety. Elevated natriuretic peptides also have anorexigenic effects via hypothalamic receptors.

3.4 Chronic Kidney Disease

Uremic toxins (e.g., indoxyl sulfate) directly depress appetite centers. Additionally, metabolic acidosis and anemia contribute to fatigue, limiting the desire or ability to eat.

3.5 Neurological Disorders

Stroke, Parkinsons disease, and multiple sclerosis can damage the brainstem or hypothalamus, interrupting normal feeding circuits. Moreover, medications used for these conditions (e.g., dopaminergic agents) can have appetitesuppressing side effects.

4. Modulating Factors

• Age: Elderly patients experience a blunted hunger response and may have comorbidities that exacerbate anorexia.
• Psychological State: Depression and anxiety, common in chronic disease, synergize with physiological signals to reduce intake.
• Medication Sideeffects: Opioids, chemotherapy, and certain antibiotics stimulate nausea or alter taste.

5. Clinical Implications

Understanding these pathways guides therapeutic strategies:

• Antiinflammatory agents: Targeted cytokine blockers (e.g., antiTNF) can improve appetite in rheumatoid arthritis and inflammatory bowel disease.
• Ghrelin mimetics: Synthetic ghrelin or ghrelinreceptor agonists (e.g., anamorelin) are under investigation for cancerrelated anorexia.
• Appetite stimulants: Megestrol acetate, mirtazapine, and dronabinol act on central pathways to boost intake.
• Nutritional counseling: Small, frequent, highenergy meals help overcome early satiety.

6. Summary

Illnessinduced anorexia results from an intricate network of peripheral signalscytokines, hormones, metabolic byproductsand central neural circuits that integrate these inputs to suppress hunger, diminish reward, and alter taste. Diseasespecific factors add layers of complexity, while age, psychological health, and medication further modulate the response. Recognizing these mechanisms is essential for developing targeted interventions that restore intake, preserve lean body mass, and improve overall outcomes.

References: 1. Fearon K, et al. Cachexia: a nutritional approach. Nat Rev Clin Oncol. 2020. 2. Dantzer R, et al. From inflammation to sickness and depression. Nat Rev Neurosci. 2021. 3. Cedernaes J, et al. The neurobiology of hunger and satiety. Nat Rev Endocrinol. 2022.